- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
PAREXEL's Inaugural Podcast Focuses on International Women's Day
PAREXEL, the global provider of biopharmaceutical services, has today published its inaugural podcast with International Women’s Day as the focus. Hosted by Harvard Kennedy School expert Siri Chilazi, the podcast features the advice and expertise of some of PAREXEL’s most remarkable women in STEM.
Commenting on this year’s campaign theme, Ubavka DeNoble M.D., Corporate Vice President, Patient Technology, PAREXEL, said: “We now talk about a balanced boardroom, a balanced government, a balanced media approach. 15 years ago, that was a strange topic. There has been huge progress. We must remember that (any imbalance) is humanity’s issue and the only one way to resolve it is to work together: males and females.”
To listen to the full podcast – which features discussion around International Women’s Day from Ubavka DeNoble M.D. – Corporate Vice President of Patient Technology, Kemi Olugemo – Senior Director, Global Therapeutic Area Head, Aida Sabo – VP Diversity, and Peyton Howell – Chief Commercial and Strategy Officer – please click here.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
